Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Arginine Stories

2011-05-20 13:05:32

Research: Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: Randomized controlled trial A dietary supplement containing an amino acid and antioxidant vitamins, given to pregnant women at high risk of pre-eclampsia, can reduce the occurrence of the disease, finds a study published on bmj.com today. Pre-eclampsia is a serious condition where abnormally high blood pressure and other disturbances develop...

2011-05-18 07:00:00

NEW YORK and SAN DIEGO, May 18, 2011 /PRNewswire/ -- Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase (ADI-PEG 20). ADI-PEG 20 kills tumor cells by depletion of the amino acid arginine. As part of the collaboration, LICR and Polaris will explore further the potential of ADI-PEG 20 as a cancer therapy and aim to identify other amino...

2011-05-12 07:00:00

SAN DIEGO, May 12, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a symposium held on Tuesday, May 24, at 1:30 p.m. China Standard Time in Taipei, Taiwan. Details about Polaris' upcoming pivotal Phase 3 clinical trial of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be presented by the principal investigator, Ghassan Abou-Alfa, M.D., of...

2011-04-11 09:13:00

SAN DIEGO, April 11, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies of ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, is synergistic with hydroxychloroquine (ChQ) in a human pancreatic cancer cell line and with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human melanoma cell lines. Both ChQ and TRAIL are known inhibitors of autophagy. These results support the commencement of Phase 1/2 clinical...

2011-04-08 07:00:00

SAN DIEGO, April 8, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer. These cancers have a high incidence of deficiencies of the arginine synthesis enzyme argininosuccinate synthetase (ASS) due to hypermethylation at the promoter of the gene that codes for ASS...

2011-03-31 07:00:00

SAN DIEGO, March 31, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the U.S. Food & Drug Administration (FDA) has approved the company's Special Protocol Assessment (SPA) for a Phase 3 clinical trial of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced hepatocellular carcinoma (HCC). The randomized, placebo-controlled, global trial will enroll approximately 600 patients who have failed prior systemic chemotherapy. The primary endpoint of the study...

2011-03-23 20:42:21

Disorders of the circulatory system- vascular diseases- are common in the developed world, and can lead to heart attacks, strokes and even death. However, treatments for these disorders, such as bypass surgery and angioplasty, themselves induce vascular injury, after which the cells of the blood vessel can over-proliferate in a way that limits blood flow. Nitric oxide (NO) is an important molecule that helps maintain the contractility and health of vascular smooth muscle cells, and multiple...

2011-03-18 08:52:00

SAN DIEGO, March 18, 2011 /PRNewswire/ -- Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the company's novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called "ADAM" (Arginine Deiminase And Mesothelioma), will evaluate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. The primary endpoint of the study is progression free...

2011-03-10 19:12:00

LAS VEGAS, March 10, 2011 /PRNewswire/ -- HCG Fast Trim and SterkHealth, LLC, are giving away a one-year free gym membership to promote the launch of HCG Fast Trim and a healthier 2011. Newly launched in 2011, HCG Fast Trim is a homeopathic appetite suppressant and weight loss product that combines amino acids and HCG that are naturally produced in the human body to amplify fat metabolism. HCG Fast Trim contains the amino acids Arginine, Carnitine and Ornithine. Each ingredient in this...

2011-02-14 07:00:00

NEW YORK and SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- Polaris Group (Polaris) and The Ludwig Institute for Cancer Research (LICR) today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating ADI-PEG 20 in the treatment of small cell lung cancer (SCLC). The trial, sponsored by LICR, is enrolling patients at Memorial Sloan-Kettering Cancer Center and Duke University Medical Center and will soon commence at St. Bartholomew's Hospital in London. This study will...